Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3339-3344

  Isobe, Kazutoshi ^a   Hata, Yoshinobu ^a   Kobayashi, Kunihiko ^a,b   Hirota, Nao ^a   Sato, Keita ^a   Sano, Go ^a   Sugino, Keishi ^a   Sakamoto, Susumu ^a   Takai, Yujiro ^a   Shibuya, Kazutoshi ^a   Takagi, Keigo ^a   Homma, Sakae ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

CellSearch system; Circulating free DNA (cfDNA); Circulating tumor cells (CTCs); Cycleave real time PCR assay; Epidermal growth factor receptor (EGFR); Lung cancer

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA DETERMINATION; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; PILOT STUDY; PRIORITY JOURNAL; REAL TIME ECHOGRAPHY; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PILOT PROJECTS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84865682334     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D and Giaccone G: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27: 6251-6256, 2009.
2. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT Chirieac LR,D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM,Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE and Yang SC: Non-small cell lung cancer. J Natl Compr Cancer Netw 8: 740-801, 2010.
3. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC and Mok TS: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, firstline study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29: 2866-2874, 2011.
4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S and Nukiwa T: Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2308, 2010.
5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K and Fukuoka M: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
6. Sequist LV, Bell DW, Lynch TJ and Haber DA: Molecular predictors of response to epidermal growth factor receptor antagonists in non-small cell lung cancer. J Clin Oncol 25: 587-595, 2007.
7. Yano S, Yamada T, Takeuchi S, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K and Noguchi M: Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 6: 2011-2017, 2011.
8. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos B: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N,Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC and Jänne PA: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039-1043, 2007.
10. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S and Yano S: Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 17: 2260-2269, 2011.
11. Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B and Nishio K: Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res 12: 3915-3921, 2006.
12. Kimura H, Suminoe M, Kasahara K, Kunitoh H, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M and Nakao S: Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 97: 778-784, 2007.
13. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D,Settleman J, Tompkins RG, Lynch TJ, Toner M and Haber DA: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377, 2008.
14. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791, 2004.
15. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW and Meropol NJ: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26: 3213-3221, 2008.
16. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D and Heller G: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a re-analysis of IMMC38 trial data. Lancet Oncol 10: 233-239, 2009.
17. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G, Ranson M, Dive C and Blackhall FH: Evaluation and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer. J Clin Oncol 29: 1556-1563, 2011.
18. Wu C, Hao H, Li L, Zhou X, Guo Z, Zhang L, Zhang X, Zhong W, Guo H, Bremner RM and Lin P: Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 4: 30-36, 2009.
19. Okumura Y, Tanaka F, Yoneda K, Hashimoto M, Takuwa T, Kondo N and Hasegawa S: Circulating tumor cells in pulmonary venous blood of primary lung cancer patients. Ann Thorac Surg 87: 1669-1675, 2009.
20. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW and Terstappen LW: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10: 6897-6904, 2004.
21. Yatabe Y, Hida T, Horio Y, Kosaka T, Takahashi T and Mitsudomi T: A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn 8: 335-341, 2006.
22. Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C and Uhr J: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8: 2073-2084, 2002.
23. Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Rahman S, Tsubota N, Tsujimura T, Kuribayashi K, Fukuoka K, Nakano T and Hasegawa S: Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 15: 6980-6986, 2009.
24. Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY and Wang J: Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small cell lung cancer. J Clin Oncol 27: 2653-2659, 2009.
25. Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T and Fukuoka M: Epidermal growth factor receptor mutation status in circulating free DNA in serum: From IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 7: 115-121, 2012.
26. Pantel K and Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 4: 448-456, 2004.
27. Gupta GP and Massagué J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006.
28. Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X and Pantel K: Circulating-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15: 1032-1038, 2009.
29. Pao W and Ladanyi M: Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 1: 4954-4955, 2007.
30. Kuang Y, Rogers A, Yeap BY, Wang L, Makrigiorgos M, Vetrand K, Thiede S, Distel RJ, and Jänne PA: Noninvasive detection of EGFR T790M in gefitinib- or erlotinib-resistant non-small cell lung cancer. Clin Cancer Res 15: 2630-2636, 2009.
31. Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, Higashiyama M, Kodama K, Imamura F and Kato K: Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 17: 7808-7815, 2011.
32. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M and Miller VA: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 17: 1616-1622, 2011.